文献速递MDS 与骨髓增殖性肿瘤

基于人群的骨髓增生异常综合征预后评分系统:瑞典MDS登记处报告

Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: a report from the Swedish MDS register.
PubMed 文献 · Br J Haematol · 2018-04-29

该研究利用瑞典全国性基于人群的MDS登记处数据,纳入2009至2013年报告的1329例患者(14%为治疗相关MDS),验证IPSS、IPSS-R和WPSS的预后价值,并报告发病率与临床特征。IPSS-R预后效力显著优于IPSS(P<0·001),较WPSS有更优趋势(P=0·05),在≤70岁患者中IPSS-R优于IPSS和WPSS。

要点

  • 瑞典MDS年粗发病率为2·9/10万居民。
  • IPSS-R预后效力显著优于IPSS(P<0·001)。
  • IPSS-R较WPSS有更优趋势(P=0·05),WPSS较IPSS有更优趋势(P=0·07)。

核心结论

  • 在瑞典全国性队列中,IPSS-R显示出最佳预测效力。

研究设计与样本

  • 基于瑞典全国性基于人群的MDS登记处数据,纳入2009至2013年报告的1329例患者,其中14%为治疗相关MDS(t-MDS)。

主要发现

  • 瑞典MDS年粗发病率为2·9/10万居民。
  • IPSS-R预后效力显著优于IPSS(P<0·001)。
  • IPSS-R较WPSS有更优趋势(P=0·05),WPSS较IPSS有更优趋势(P=0·07)。
  • 在年龄≤70岁患者中,IPSS-R优于IPSS和WPSS。
  • t-MDS患者结局较de novo MDS(d-MDS)更差,但预后评分系统在d-MDS和t-MDS中的有效性相当。

关键数值与推荐

  • IPSS-R vs IPSS:P<0·001,IPSS-R预后效力显著更优。
  • IPSS-R vs WPSS:P=0·05,IPSS-R有更优趋势。
  • WPSS vs IPSS:P=0·07,WPSS有更优趋势。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The myelodysplastic syndromes (MDS) have highly variable outcomes and prognostic scoring systems are important tools for risk assessment and to guide therapeutic decisions. However, few population-based studies have compared the value of the different scoring systems. With data from the nationwide Swedish population-based MDS register we validated the International Prognostic Scoring System (IPSS), revised IPSS (IPSS-R) and the World Health Organization (WHO) Classification-based Prognostic Scoring System (WPSS). We also present population-based data on incidence, clinical characteristics including detailed cytogenetics and outcome from the register. The study encompassed 1329 patients reported to the register between 2009 and 2013, 14% of these had therapy-related MDS (t-MDS). Based on the MDS register, the yearly crude incidence of MDS in Sweden was 2·9 per 100 000 inhabitants. IPSS-R had a significantly better prognostic power than IPSS (P < 0·001). There was a trend for better prognostic power of IPSS-R compared to WPSS (P = 0·05) and for WPSS compared to IPSS (P = 0·07). IPSS-R was superior to both IPSS and WPSS for patients aged ≤70 years. Patients with t-MDS had a worse outcome compared to de novo MDS (d-MDS), however, the validity of the prognostic scoring systems was comparable for d-MDS and t-MDS. In conclusion, population-based studies are important to validate prognostic scores in a 'real-world' setting. In our nationwide cohort, the IPSS-R showed the best predictive power.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Moreno Berggren D, Folkvaljon Y, Engvall M, et al. Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: a report from the Swedish MDS register. Br J Haematol. 2018. PMID: 29707769. doi:10.1111/bjh.15243

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。